| Covidien Buys Ev3 for $2.6 Billion Covidien said it is buying vascular device maker ev3 for $2.6 billion in cash as it continues to remake its business. online.wsj.com |
Guidelines Would Trim New Doctors' Hours to Reduce Errors Amid continued concern about errors by overworked medical residents, hospitals would be forced to sharply curtail shifts and increase supervision of some doctors-in-training under proposed new guidelines for residency programs. online.wsj.com |
Sigma Agrees to Sell Drug Unit to Aspen Sigma Pharmaceuticals will sell its pharmaceutical division to South Africa's Aspen Pharmacare for $803.5 million. online.wsj.com |
Idenix Hopes to Resume Course With Hepatitis C Drugs by Year's End The Burrill Report submits: By Michael FitzhughIdenix Pharmaceuticals (IDIX) halted a mid-stage study of two hepatitis C drugs after the U.S. Food and Drug Administration ordered it to suspend the trial over safety concerns. The news led investors to sink the company's shares on worries about the program's future. Complete Story » seekingalpha.com |
U.K. Cost Body Declines to Back Cancer Drug The U.K. health-cost body has declined to back Novartis's kidney-cancer drug Afinitor as a second line treatment due to lingering cost and efficiency concerns. online.wsj.com |